Invasive Fungal Infection Therapeutics Market Size | 2032

Report Description

Invasive Fungal Infection Therapeutics Market Outlook 2032

The global invasive fungal infection therapeutics market size was USD 7.8 Billion in 2023 and is projected to reach USD 11.6 Billion by 2032, expanding at a CAGR of 4.5% during 2024–2032. The market growth is attributed to the necessity for novel treatment, growing incidence of fungal infections, and rising number of immunocompromised people or geriatric population.

Fungal infections that go deep into the tissues and result in long-lasting illness are known as invasive fungal infections or IFIs. IFIs, which are brought on by yeasts and moulds, are commonly observed in immunocompromised and impaired individuals. Weak immunity is IFI's primary cause. Bloodstream infections (mycosis) or secondary transmission to organs such as liver, spleen, eyes, bone, heart valves, and central nervous system are the two ways the disease manifests itself. According to the statistics given in a research article published in Frontiers, 1 billion people suffer from fungal infections, leading to more than 1.6 million deaths per year.

• In January 2024, the Lancet published study that provided the compiled statistics of the prevalence of different types of fungal infections from 2010 – 2023. According to these revised figures, there are around 6.5 million invasive fungal infections and 3.08 million fatalities annually, with approximately 2.5 million (68 percent; range: 35–90) being directly related.

• In October 2022, the World Health Organization (WHO) listed the most health threatening fungi. The list included 19 different fungi, which were listed into three categories based on their risk factors: medium, high, and critical. Fungi such as Candida auris, Cryptococcus neoformans, Aspergillus fumigatus, and Candida albicans were grouped critical. Other such as Mucorales, cause mucormycosis or Black Fungus were grouped under high. 
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) in Invasive Fungal Infection Therapeutics Market

Artificial Intelligence is boosting the impact on the invasive fungal infection therapeutics market. Early and precise identification of fungal infection has a critical role in controlling it in its early stages, thereby averting the development of a potentially fatal scenario. The discipline of fungal diagnostics has moved significantly from conventional techniques of microscopy and culturing to more sophisticated non-culture-based instruments in response to changing demands of clinical mycology.

The field of fungal diagnostics is continuously improving with the introduction of potent techniques such as T2 Candida, novel PCR assays, microfluidic chip technology, next-generation sequencing, new-generation biosensors, tools based on nanotechnology, and artificial intelligence-based models. Hence, formations of biosensors and digital next-gen sequencing are driving the revenue growth of the market rapidly.

Consequently, inaccuracies and delays in treatment result in increased hospital expenses, mortality rates, and migration. Therefore, combining artificial intelligence with single-cell Raman spectroscopy to quickly identify infectious fungus is currently in practice.

Invasive Fungal Infection Therapeutics Market Dynamics

Get Free Sample Report

Major Drivers

Increasing research to develop novel treatments and the growing incidence of fungal infections are driving the market. Furthermore, it is projected that the rising number of pharmaceuticals in the pipeline is expected to improve the market potential during the forecast period. The growth of the market is attributed to the rising healthcare spending and increasing awareness, particularly in emerging economies and underserved markets.

Existing Restraints

Complexity of manufacturing novel therapies is restraining the market revenue. Moreover, the high costs associated with the R&D activities, time taking process of approvals from regulatory bodies, and numerous side effects related to this treatment is hindering the market. Large number of commercial obstacles exist, including restricted efficacy of specific antifungal medications and high cost of antifungal medication, low down the selling of these drugs.

Drug-resistant fungus strains, including azole-resistant Aspergillus fumigatus, have emerged, making it hard to treat infections caused by infections and decreasing efficacy of currently available antifungal medications. Other challenges include antimicrobial resistance, and the   lack of advance healthcare professionals.

Emerging Opportunities

­The invasive fungal infection therapeutics offer opportunities for novel drug development, such as mechanism-based approaches targeting specific fungal pathways, and combination therapies. Upcoming immunomodulatory therapies by antifungal nanoparticles is anticipated to harness the microbiome to combat fungal pathogens. Increasing developments of diagnostics and personalized medicine are expected improve the identification of fungal species & antifungal resistance profiles, genetic testing, and pharmacogenomics. Rising improvisations in delivery systems and patient care is expected to develop long-acting injectables, nebulized antifungals, telehealth, remote monitoring, and patient education.

Scope of the Invasive Fungal Infection Therapeutics Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Invasive Fungal Infection Therapeutics Market Segment Insights

Drug Type Segment Analysis

Based on drug type, the invasive fungal infection therapeutics market is divided into Echinocandins Triazoles, Lipid Formulation Amphotericin B, Amphotericin B Deoxycholate, and Polyenes. The Triazoles segment held a major share of the market in 2023. Triazoles are significant pharmacophores due to their rigidity, solubility, hydrogen bonding ability, and dipole character, which allow them to interact with biological receptors with high affinity, thus making them strong antifungal drug. Among the earliest triazoles to be synthesized were itraconazole and fluconazole; however, their applications were restricted.

The Polyenes segment is expected to expand at a significant pace in the coming years. Polyenes are a class of antifungal drugs that work by targeting the fungal cell membrane. The broad-spectrum activity and affordability of polyenes contribute to the significant rise in its revenue share.  

Get Free Sample Report

Disease Type Segment Analysis

On the basis of disease type, the global invasive fungal infection therapeutics market is segregated into Coccidioidomycosis & Scedosporiosis, Invasive Aspergillosis, Cryptococcal Meningitis, Intra-abdominal Candidiasis, Histoplasmosis Acute Pulmonary, Candidaemia, and Invasive Candidiasis. The invasive candidiasis segment held the largest market share in 2023 due to the large immunosuppressed patient pool and ubiquitous distribution of the infection. Additionally, increasing multiplication and replication of Candida albicans boost the revenue share of this segment.

• In April 2022, Centre for Host-Microbiome Interactions stated that, every year, the invasive and widespread disease caused by the fungus pathogen Candida albicans results in about 150 million mucosal infections and around 200,000 fatalities in vulnerable populations.

The invasive aspergillosis segment is anticipated to expand at a substantial CAGR during the forecast period. Rise in immunocompromised patients, including those receiving organ transplants or those suffering from cancer, and the rise in nosocomial fungal infections are boosting the revenue share of this segment. Moreover, the creation of novel antifungal medications and the increased understanding of the significance of early detection and timely treatment of invasive aspergillosis are driving the segment's revenue expansion.

Distribution Channel Segment Analysis

Based on distribution channel, the invasive fungal infection therapeutics market is segmented into hospital pharmacies, retail pharmacies, online pharmacies. The retail pharmacy segment led the market in terms of revenue in 2023. The retail pharmacy segment was dominating the global market accounting for one-third of the total revenue share of all the pharmacies and number of prescription prepared.

• In November 2021, according to McKinsey Pharmacy Consumer Survey, retail chains dispense about 138,000 prescriptions annually per store, or over 50% more than supermarkets, making them the largest prescription distributors per retail site.

The online pharmacy segment is projected to register a robust growth rate during the assessment years. According to RedSeer survey, the segment is attracting investors, as over 70% customers are using e-pharmacy post the pandemic. The segment is expected to rise significantly during the forecast period due to the ease of access, cost effectiveness, and availability of a range of medicines.

Get Free Sample Report

Regional Outlook

In terms of region, the global invasive fungal infection therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the global market with the largest market revenue share in 2023. This significant revenue share is attributed to the increasing cases of infectious fungal infections, rising healthcare standards, and the presence of majority of market players in the region.

The market in Europe is projected to grow at a significant pace in the years to come owing to the rising number of cases of fungal infections. Furthermore, increasing R&D activities for drug discovery in this region is driving the market in the region.